Search results for " Pharmacy"

showing 10 items of 365 documents

In vitro glucuronidation of 7-hydroxycoumarin derivatives in intestine and liver microsomes of Beagle dogs

2019

Beagle dog is a standard animal model for evaluating nonclinical pharmacokinetics of new drug candidates. Glucuronidation in intestine and liver is an important first-pass drug metabolic pathway, especially for phenolic compounds. This study evaluated the glucuronidation characteristics of several 7-hydroxycoumarin derivatives in beagle dog's intestine and liver in vitro. To this end, glucuronidation rates of 7-hydroxycoumarin (compound 1), 7-hydroxy-4-trifluoromethylcoumarin (2), 6-methoxy-7-hydroxycoumarin (3), 7-hydroxy-3-(4-tolyl)coumarin (4), 3-(4-fluorophenyl)coumarin (5), 7-hydroxy-3-(4-hydroxyphenyl)coumarin (6), 7-hydroxy-3-(4-methoxyphenyl)coumarin (7), and 7-hydroxy-3-(1H-1,2,4-t…

entsyymitColonGlucuronidationPharmaceutical Science02 engineering and technologyliver030226 pharmacology & pharmacyBeaglekoira7-hydroxycoumarin derivative03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDogsGlucuronidesPharmacokineticsMicrosomesenzyme kineticsIntestine SmallmedicineAnimalsHumansUmbelliferonesGlucuronosyltransferasekumariinitaineenvaihduntachemistry.chemical_classificationChemistryglucuronidationdog intestinemaksaMetabolismlääkeaineet021001 nanoscience & nanotechnologyCoumarinSmall intestineEnzymemedicine.anatomical_structureBiochemistryLiverfarmakokinetiikkasuolistoMicrosomekoe-eläinmallit0210 nano-technology
researchProduct

Incorporation of dynamic boronate links and Ag nanoparticles into PVA hydrogels for pH-Regulated and prolonged release of methotrexate

2021

Abstract In this study, pH-responsive hydrogels based on PVA-boronate crosslinks were prepared via a simple route and used for controlled and targeted delivery of anticancer drug methotrexate. A double network (DN) hydrogel composed of didiol-boronate/PVA complex as the first network and PVA crystallites generated by a freeze-thaw process as the second one was developed. The swelling of PVA-boronate DN hydrogels demonstrated high sensitivity to multiple stimuli including the pH, temperature, and ionic strength of the media thanks to the dynamic boronate links in the first network. Moreover, unlike previously reported hydrogels based on the boronate linkages, the new DN hydrogels preserved t…

inorganic chemicalsChemistrytechnology industry and agricultureCancer therapyPharmaceutical ScienceAg nanoparticlesmacromolecular substances02 engineering and technology021001 nanoscience & nanotechnologycomplex mixtures030226 pharmacology & pharmacyAnticancer drug03 medical and health sciences0302 clinical medicineChemical engineeringProlonged releaseIonic strengthSelf-healing hydrogelsmedicineMethotrexateSwellingmedicine.symptom0210 nano-technologymedicine.drugJournal of Drug Delivery Science and Technology
researchProduct

Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses

2019

The present work aimed to explain the differences in oral performance in fasted humans who were categorized into groups based on the three different drug product formulations of dexketoprofen trometamol (DKT) salt&mdash

liquid–liquid phase separationSALT DISPROPORTIONATIONgastrointestinal absorptionSodiumlcsh:RS1-441Pharmaceutical ScienceExcipientchemistry.chemical_elementSalt (chemistry)Hydrochloric acidSOLUBILITYCalciumBioequivalenceArticlelcsh:Pharmacy and materia medicachemistry.chemical_compoundFLUIDSEMAoral absorptionABSORPTIONmedicinePharmacology & PharmacySUPERSATURATED SOLUTIONSdexketoprofenSimulationchemistry.chemical_classificationScience & TechnologyChemistryliquid-liquid phase separationPhosphateDexketoprofenSIMILARITIESgastrointestinal simulatorin vitro dissolutionIN-VITRO DISSOLUTIONLife Sciences & BiomedicineVIVO DISSOLUTIONMETHODOLOGYmicroscopy imagingmedicine.drugPharmaceutics
researchProduct

Robotic i.v. medication compounding: Recommendations from the international community of APOTECAchemo users.

2016

Purpose The development of recommendations for advancing automated i.v. medication compounding is described. Summary Managing the shift from manual to robotic compounding of i.v. therapies requires an awareness of how automation affects practice and how to best implement robotics into current practice. An international panel of pharmacy professionals, researchers, and technology leaders with experience in i.v. robotics collaborated during a two-day meeting in August 2014 to define a general set of principles to broaden the understanding of the fundamental elements of robotic compounding worldwide. Participants were divided into four working groups (technology and safety; drugs and products;…

media_common.quotation_subjectDrug CompoundingPharmacy030226 pharmacology & pharmacy03 medical and health sciencesAutomation0302 clinical medicineNursingSurveys and QuestionnairesMedicineHumansQuality (business)Set (psychology)media_commonPharmacologyDrug compoundingMedical educationbusiness.industryHealth PolicyInternational communityRoboticsCompoundingCurrent practice030220 oncology & carcinogenesisPractice Guidelines as TopicAdministration IntravenousWorking groupbusinessPharmacy Service HospitalAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
researchProduct

Medication adherence and persistence in type 2 diabetes mellitus: perspectives of patients, physicians and pharmacists on the Spanish health care sys…

2017

Elena Labrador Barba,1 Marta Rodríguez de Miguel,1 Antonio Hernández-Mijares,2,3 Francisco Javier Alonso-Moreno,4 Maria Luisa Orera Peña,1 Susana Aceituno,5 María José Faus Dader6 1Department of Medicine, Mylan, Madrid, 2Department of Endocrinology and Nutrition, Doctor Peset University Hospital, Valencia, 3Department of Medicine, University of Valencia, Valencia, 4Department for Primary Health Care, Centro de Salud Sillería, Toledo, 5Outcomes’10, Castellon, 6Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Granada, Granada, Spain Objective: A good relationship between diabetes pa…

medicine.medical_specialtyActivities of daily livingtype 2 diabetes mellitusMedicine (miscellaneous)030209 endocrinology & metabolismLikert scale03 medical and health sciences0302 clinical medicineDiabetes mellitusHealth caremedicine030212 general & internal medicineadherenceAdverse effectPharmacology Toxicology and Pharmaceutics (miscellaneous)Original Researchbusiness.industryHealth PolicyfactorsType 2 Diabetes Mellituspersistencemedicine.diseaseClinical pharmacyPatient Preference and AdherenceFamily medicinestrategiesObservational studybusinessSocial Sciences (miscellaneous)Patient preference and adherence
researchProduct

Future perspectives of the pharmacological management of diabetic dyslipidemia

2019

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase…

medicine.medical_specialtyApolipoprotein Bmedicine.drug_classglucagon like peptide-1 receptor agonist (GLP-1RA)Fibrate030226 pharmacology & pharmacystatins03 medical and health sciences0302 clinical medicineInsulin resistanceEzetimibeInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsOmega 3 fatty acidDyslipidemiasHypolipidemic Agentsfibratebiologybusiness.industrydyslipidemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineLipidmedicine.diseasesodium/glucose cotransporter 2 inhibitors (SGLT-2is)LipidsEndocrinologyDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisDipeptidyl peptidase-4 inhibitors (DPP-4is)Dietary Supplementsbiology.proteinKexinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessDyslipidemiamedicine.drugezetimibeproprotein convertase subtilisin/kexin type 9 (PCSK9)
researchProduct

Dispensing of the psychotropic drugs via community pharmacies during 2005–2006 years

2007

medicine.medical_specialtyCommunity pharmaciesbusiness.industryFamily medicinemedicinePharmaceutical ScienceHospital pharmacybusinessEuropean Journal of Pharmaceutical Sciences
researchProduct

Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum

2019

Introduction: Pyoderma gangrenosum (PG) is a noninfectious, reactive inflammatory neutrophilic dermatosis that is commonly associated with autoimmune and neoplastic disorders. There are emerging diagnostic tools and treatment options for PG.Area covered: The diagnosis of PG should be seriously considered when managing ulcers to avoid unnecessary medical and surgical complications with prompt and suitable treatment. There are no standardized treatment guidelines for PG, and current therapy largely depends on the severity and progression of the disease. Systemic corticosteroids, immunosuppressant therapy, and biologic agents remain mainstay therapies. In this article, we present a literature …

medicine.medical_specialtyDiseaseDiagnostic toolsSeverity of Illness Index030226 pharmacology & pharmacySystemic therapyBiological Factors03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesmedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsIntensive care medicineClinical treatmentbusiness.industryGeneral MedicineGold standard (test)medicine.diseasePyoderma GangrenosumBiologic AgentsNeutrophilic dermatosis030220 oncology & carcinogenesisDisease ProgressionDermatologic AgentsbusinessImmunosuppressive AgentsPyoderma gangrenosumExpert Review of Clinical Pharmacology
researchProduct

Prolonged-release buprenorphine formulations: Perspectives for clinical practice

2020

International audience; Buprenorphine and methadone are the two main opioid agonist treatments approved for opioid use disorder. Buprenorphine is a partial agonist of the mu opioid receptors, which has been merely available through sublingual form until now. In practice, the use of buprenorphine is smoother than that of methadone, and it induces reduced risks of overdose. However, sublingual buprenorphine also exposes to risks (e.g., withdrawal, misuse) and constraints (e.g., daily intake). Three new galenic formulations of prolonged-release buprenorphine (PRB) are being commercialized and should allow some improvements in patients' comfort and safety. This narrative review aims to describe…

medicine.medical_specialtyDoseNarcotic Antagonists[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthReceptors Opioid mu030226 pharmacology & pharmacyPartial agonistOpioid dependenceDependance aux opioides03 medical and health sciencesSubcutaneous injection0302 clinical medicineProlonged releasemedicineHumansProlonged-releasePharmacology (medical)OpiacésAction prolongeebusiness.industryOpioid use disorderOpioid-Related Disordersmedicine.disease3. Good healthBuprenorphineAnalgesics OpioidOpiatesOpioid[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthEmergency medicinebusinessSubstitutionMethadoneBuprenorphinemedicine.drugMethadone
researchProduct

Unpredictable Performance of pH-Dependent Coatings Accentuates the Need for Improved Predictive in Vitro Test Systems.

2017

First introduced in the second half of the 19th century, enteric coatings are commonly used to protect acid-labile drugs, reduce the risk of gastric side effects due to irritating drugs, or for local drug delivery to the lower gastrointestinal (GI) tract. The currently available enteric-coatings are based on pH-sensitive weakly acidic polymers. Despite the long history of their use, the causes behind their performance often being unpredictable have not been properly investigated with most of the attention being focused only on the gastric emptying. However, little attention has been given to the postgastric emptying disintegration and dissolution of these dosage forms. This lack of attentio…

medicine.medical_specialtyDrug LiberationIn vitro testChemistry PharmaceuticalPharmaceutical SciencePh dependentBiological Availability02 engineering and technologyPharmacologyIn Vitro Techniques030226 pharmacology & pharmacyDosage formBiopharmaceuticsExcipients03 medical and health sciences0302 clinical medicineDrug DiscoveryIntestine SmallmedicineIntensive care medicineGastric emptyingbusiness.industryHydrogen-Ion Concentration021001 nanoscience & nanotechnologyEnteric coatingBioavailabilityDrug LiberationSolubilityDrug deliveryMolecular MedicineTablets Enteric-Coated0210 nano-technologybusinessmedicine.drugMolecular pharmaceutics
researchProduct